Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D04EIE
|
||||
| Former ID |
DNC009630
|
||||
| Drug Name |
N5-(1-iminopent-3-enyl)-L-ornithine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C10H19N3O2
|
||||
| Canonical SMILES |
CC=CCC(=NCCCC(C(=O)O)N)N
|
||||
| InChI |
1S/C10H19N3O2/c1-2-3-6-9(12)13-7-4-5-8(11)10(14)15/h2-3,8H,4-7,11H2,1H3,(H2,12,13)(H,14,15)/b3-2+/t8-/m0/s1
|
||||
| InChIKey |
JUSNBVJTFYDFKR-SGJFDWMWSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Nitric-oxide synthase, brain | Target Info | Inhibitor | [1] | |
| BioCyc Pathway | Citrulline-nitric oxide cycle | ||||
| KEGG Pathway | Arginine and proline metabolism | ||||
| Metabolic pathways | |||||
| Calcium signaling pathway | |||||
| Phagosome | |||||
| Circadian entrainment | |||||
| Long-term depression | |||||
| Salivary secretion | |||||
| Alzheimer's disease | |||||
| Amyotrophic lateral sclerosis (ALS) | |||||
| NetPath Pathway | EGFR1 Signaling Pathway | ||||
| PANTHER Pathway | CCKR signaling map ST | ||||
| PathWhiz Pathway | Arginine and Proline Metabolism | ||||
| Reactome | ROS production in response to bacteria | ||||
| Nitric oxide stimulates guanylate cyclase | |||||
| WikiPathways | Monoamine Transport | ||||
| Myometrial Relaxation and Contraction Pathways | |||||
| Amyotrophic lateral sclerosis (ALS) | |||||
| Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | |||||
| Spinal Cord Injury | |||||
| Alzheimers Disease | |||||
| Effects of Nitric Oxide | |||||
| Serotonin Transporter Activity | |||||
| References | |||||
| REF 1 | Bioorg Med Chem. 2008 Dec 15;16(24):10205-9. Epub 2008 Oct 29.Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.